NCT02735291View on ClinicalTrials.gov

Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia

NAActive, not recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2025

Conditions
Leukemia
Interventions
BIOLOGICAL

CD19-targeted CAR-T cells

This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..

Trial Locations (2)

210000

No. 454 Hospital of People'S Liberation Army, Nanjing

230601

The Second Hospital of Anhui Medical University, Hefei

All Listed Sponsors
collaborator

The Second Hospital of Anhui Medical University

OTHER

lead

Sinobioway Cell Therapy Co., Ltd.

INDUSTRY

NCT02735291 - Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia | Biotech Hunter | Biotech Hunter